Investing is often filled with tough choices and opportunity costs. This game segment from The Motley Fool's Where The Money Is poses a hypothetical question:
Would you rather short Johnson & Johnson (JNJ +1.09%) or buy Dendreon (NASDAQ: DNDN)?
Healthcare analysts David Williamson and Michael Douglass continue their game of "would you rather" by discussing a blue chip stalwart and a biotech struggling with lackluster sales. Watch and find out which strategy David chooses and his arguments for it.
